Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B6ZM0X53 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 14.75 14.50 15.00 14.75 14.75 14.75 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 11.0 -18.9 -21.3 - 12

hVIVO plc hVIVO to present at ERS International Congress

27/09/2019 7:01am

RNS Non-Regulatory


TIDMHVO

hVIVO plc

27 September 2019

hVIVO plc

("hVIVO" or the "Company")

hVIVO to present at the upcoming 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain

London, UK - 27 September 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business supporting product development for companies developing antivirals, vaccines and respiratory therapeutics today announced it will be presenting at the European Respiratory Society Congress being held on September 28 - October 2, 2019 at the IFEMA, Feria de Madrid, Madrid, Spain.

The first presentation will evaluate the use of lower respiratory symptoms as a key endpoint to be used in trials along with the relationships between the endpoint and clinical markers such as lung function and asthma control. The second presentation will focus on the patterns of the immune response to a viral exacerbation in asthmatics and the timing profile of white blood cells as well as nasal and blood immune biomarkers. These presentations highlight the utility of the hVIVO viral challenge model as well as help inform trial design and endpoint selection.

Andrew Catchpole, Director, Clinical Science, commented; "We are delighted that our abstracts have been accepted for presentation at the prestigious ERS International Congress. The data summarised in the posters is encouraging and supports our belief that the challenge model is not only helpful as a proof-of-concept for the effectiveness of agents directed at the viruses, but also as proof-of-mechanism for novel products in diseases where respiratory viruses are known to induce exacerbations."

Poster discussion presentation details:

Title: A key endpoint in viral challenge models of asthma exacerbations Poster

Authors: Michael. A. Ghebre, Alan S. Bell, Alex J. Mann

Date & Time: 29.09.2019 at 08:30 CEST

Session Category: Airway Physiology 08:30-10:30

Presenter: Alan S. Bell, Director of Translational Operations

Location: 6D

Conference Reference Number: 347

Oral presentation details:

Title: Temporal relationships of cytokines, chemokines and cellular biomarkers during Human Rhinovirus (HRV) infection in asthmatics

Authors: Alex J Mann, Michael A Ghebre, Alan S Bell

Date & Time: 01.10.2019 at 10:15 CEST

Session Category: Blood Eosinophils and More in Airway Diseases 08:30-10:30

Presenter: Alan S. Bell, Director of Translational Operations

Location: 8A

Conference Reference Number: 3564

A copy of the presentation materials will be made available here: https://hvivo.com/news-media/scientific-papers/

For further information please contact:

 
 hVIVO plc 
 Fleur Wood (EVP, Investor Relations & Communications)    +44 207 756 1300 
 
 Numis Securities Limited                                  +44 207 260 1000 
 Freddie Barnfield / Huw Jeremy (Nominated Adviser) 
 James Black (Corporate Broking) 
 
 FTI Consulting 
 Simon Conway / Victoria Foster Mitchell                  +44 203 727 1000 
 

Notes to Editors:

hVIVO is an industry leading clinical development services business supporting product development for customers developing antivirals, vaccines and respiratory therapeutics. Leveraging human disease models in human rhinovirus (HRV), RSV, Influenza (Flu) Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO platform illuminates the entire disease cycle in people from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted 56 clinical studies and inoculated over 2900 volunteers.

Forward-looking statements

This announcement includes statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms anticipates, believes, estimates, expects, intends, may, plans, projects, should or will, or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. Any forward-looking statements in this announcement reflect the Group's (or, as the case may be, the hVIVO directors') current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's operations, results of operations and growth strategy. Investors should specifically consider the factors identified in this announcement which could cause actual results to differ before making an investment decision.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRABRGDCDSDBGCL

(END) Dow Jones Newswires

September 27, 2019 02:01 ET (06:01 GMT)

1 Year Hvivo Chart

1 Year Hvivo Chart

1 Month Hvivo Chart

1 Month Hvivo Chart
Your Recent History
LSE
HVO
Hvivo
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191122 21:30:02